PILERI, Alessandro
PILERI, Alessandro
Dip. MEDICINA ED ONCOLOGIA SPERIMENTALE (attivo dal 01/01/1900 al 30/04/2013)
Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies:correlation with diagnosis and disease status.
1988-01-01 Dianzani U; Pileri A; Boccadoro M; Palumbo A; Pioppo P; Bianchi A; Camponi A; Fossati G; Battaglio S; Massaia M
Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma.
1998-01-01 Majolino I; Corradini P; Scimè R; Santoro A; Tarella C; Cavallaro AM; Palumbo A; Indovina A; Caracciolo D; Boccadoro M; Marcenò R; Pileri A.
Altered expression of growth-regulated protoncogenes in human malignant plasma cells.
1989-01-01 Palumbo A; Pileri A; Dianzani U; Massaia M; Boccadoro M; Calabretta B
An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy.
1999-01-01 Boccadoro M; Tarella C; Palumbo A; Argentino C; Triolo S; Dominietto A; Callea V; Lauta VM; Molica S; Musto P; Marmont F; Gianni AM; Pileri A
Analysis of the breakpoint cluster region in essential thrombocythemia.
1990-01-01 Corradini P; Palumbo A; Battaglio S; Ponzio G; Boccadoro M; Pileri A
Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation.
1997-01-01 Campana S; Corradini P; Astolfi M; Ladetto M; Cinque F; Novero D; Tarella C; Pileri A.
Antigenic phenotype of myelomonocytic progenitors (CFU-GM) in chronic myeloproliferative disorders.
1986-01-01 Ferrero D; Tarella C; Pregno P; Pileri A; Gallo E.
Autologous bone marrow transplantation in acute myeloid leukemia after in-vitro purging with an anti-lacto-N-fucopentaose III antibody and rabbit complement.
1987-01-01 Ferrero D; De Fabritiis P; Amadori S; De Felice L; Gallo E; Meloni G; Pregno P; Pulsoni A; Simone F; Tarella C; Pileri A; Rovera G; Mandelli F
Biology of the human myeloma cell population. I.Macromolecular characteristics.
1978-01-01 Hulling, N; Boccadoro, M; Masera, P; Pileri, A
Both early and committed progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF.
1995-01-01 C. TARELLA; BENEDETTI G; CARACCIOLO D; CASTELLINO C; CHERASCO C; BONDESAN P; OMEDE' P; RUGGIERI D; GIANNI AM; PILERI A
Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short interval between drug courses severely impair progenitor mobilization.
1995-01-01 C. TARELLA; CARACCIOLO D; GAVAROTTI P; BONDESAN P; CHERASCO C; OMEDE' P; BREGNI M; SIENA S; GIANNI AM; PILERI A.
Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma.
1996-01-01 Corradini P; Ladetto M; Astolfi M; Voena C; Tarella C; Bacigalupo A; Pileri A
Clinical and trichoscopic features in 18 cases of Folliculotropic Mycosis Fungoides with scalp involvement
2021-01-01 Gallo G.; Pileri A.; Starace M.; Alessandrini A.; Guglielmo A.; Ribero S.; Quaglino P.; Piraccini B.M.
Conditions influencing the expansion of the circulating hemopoietic progenitor cell compartment.
1990-01-01 Tarella C; Ferrero D; Siena S; Gallo E; Bondesan P; Bregni M; Pileri A; Gianni AM.
Conventional induction treatments do not influence overall survival in multiple myeloma.
1997-01-01 Boccadoro M; Palumbo A; Argentino C; Dominietto A; Frieri R; Avvisati G; Comotti B; LautaVM; Liberati M; Marmont F; Musto P; Tribalto M; Pileri A.
Current therapeutic options for multiple myeloma.
1996-01-01 Pileri A; Palumbo A; Boccadoro M
Cyclophosphamide (3.6 g/m2) therapy with G-CSF support for resistant myeloma.
1994-01-01 Palumbo A; Boccadoro M; Triolo S; Bruno B; Pileri A
Cytofluorimetric evaluation of plasma cell proliferative activity in monoclonal gammopathies.
1998-01-01 Triolo R; Omede P; Giaretta F; Ravaglia R; Battaglio S; Palumbo A; Dominietto A; Argentino C; Triolo S; Pileri A; Boccadoro M.
Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue
2018-01-01 Ciavarella, S.; Vegliante, M.C.; Fabbri, M.; De Summa, S.; Melle, F.; Motta, G.; De Iuliis, V.; Opinto, G.; Enjuanes, A.; Rega, S.; Gulino, A.; Agostinelli, C.; Scattone, A.; Tommasi, S.; Mangia, A.; Mele, F.; Simone, G.; Zito, A.F.; Ingravallo, G.; Vitolo, U.; Chiappella, A.; Tarella, C.; Gianni, A.M.; Rambaldi, A.; Zinzani, P.L.; Casadei, B.; Derenzini, E.; Loseto, G.; Pileri, A.; Tabanelli, V.; Fiori, S.; Rivas-Delgado, A.; López-Guillermo, A.; Venesio, T.; Sapino, A.; Campo, E.; Tripodo, C.; Guarini, A.; Pileri, S.A.
Dose- intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients.
1999-01-01 Palumbo A; Triolo S; Argentino C; Bringhen S; Dominietto A; Rus C; Omedè P; Tarella C; Pileri A; Boccadoro M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies:correlation with diagnosis and disease status. | 1988 | Dianzani U; Pileri A; Boccadoro M; Palumbo A; Pioppo P; Bianchi A; Camponi A; Fossati G; Battaglio S; Massaia M | |
| Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. | 1998 | Majolino I; Corradini P; Scimè R; Santoro A; Tarella C; Cavallaro AM; Palumbo A; Indovina A; Caracciolo D; Boccadoro M; Marcenò R; Pileri A. | |
| Altered expression of growth-regulated protoncogenes in human malignant plasma cells. | 1989 | Palumbo A; Pileri A; Dianzani U; Massaia M; Boccadoro M; Calabretta B | |
| An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy. | 1999 | Boccadoro M; Tarella C; Palumbo A; Argentino C; Triolo S; Dominietto A; Callea V; Lauta VM; Molica S; Musto P; Marmont F; Gianni AM; Pileri A | |
| Analysis of the breakpoint cluster region in essential thrombocythemia. | 1990 | Corradini P; Palumbo A; Battaglio S; Ponzio G; Boccadoro M; Pileri A | |
| Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation. | 1997 | Campana S; Corradini P; Astolfi M; Ladetto M; Cinque F; Novero D; Tarella C; Pileri A. | |
| Antigenic phenotype of myelomonocytic progenitors (CFU-GM) in chronic myeloproliferative disorders. | 1986 | Ferrero D; Tarella C; Pregno P; Pileri A; Gallo E. | |
| Autologous bone marrow transplantation in acute myeloid leukemia after in-vitro purging with an anti-lacto-N-fucopentaose III antibody and rabbit complement. | 1987 | Ferrero D; De Fabritiis P; Amadori S; De Felice L; Gallo E; Meloni G; Pregno P; Pulsoni A; Simone F; Tarella C; Pileri A; Rovera G; Mandelli F | |
| Biology of the human myeloma cell population. I.Macromolecular characteristics. | 1978 | Hulling, N; Boccadoro, M; Masera, P; Pileri, A | |
| Both early and committed progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF. | 1995 | C. TARELLA; BENEDETTI G; CARACCIOLO D; CASTELLINO C; CHERASCO C; BONDESAN P; OMEDE' P; RUGGIERI D; GIANNI AM; PILERI A | |
| Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short interval between drug courses severely impair progenitor mobilization. | 1995 | C. TARELLA; CARACCIOLO D; GAVAROTTI P; BONDESAN P; CHERASCO C; OMEDE' P; BREGNI M; SIENA S; GIANNI AM; PILERI A. | |
| Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. | 1996 | Corradini P; Ladetto M; Astolfi M; Voena C; Tarella C; Bacigalupo A; Pileri A | |
| Clinical and trichoscopic features in 18 cases of Folliculotropic Mycosis Fungoides with scalp involvement | 2021 | Gallo G.; Pileri A.; Starace M.; Alessandrini A.; Guglielmo A.; Ribero S.; Quaglino P.; Piraccini B.M. | |
| Conditions influencing the expansion of the circulating hemopoietic progenitor cell compartment. | 1990 | Tarella C; Ferrero D; Siena S; Gallo E; Bondesan P; Bregni M; Pileri A; Gianni AM. | |
| Conventional induction treatments do not influence overall survival in multiple myeloma. | 1997 | Boccadoro M; Palumbo A; Argentino C; Dominietto A; Frieri R; Avvisati G; Comotti B; LautaVM; Liberati M; Marmont F; Musto P; Tribalto M; Pileri A. | |
| Current therapeutic options for multiple myeloma. | 1996 | Pileri A; Palumbo A; Boccadoro M | |
| Cyclophosphamide (3.6 g/m2) therapy with G-CSF support for resistant myeloma. | 1994 | Palumbo A; Boccadoro M; Triolo S; Bruno B; Pileri A | |
| Cytofluorimetric evaluation of plasma cell proliferative activity in monoclonal gammopathies. | 1998 | Triolo R; Omede P; Giaretta F; Ravaglia R; Battaglio S; Palumbo A; Dominietto A; Argentino C; Triolo S; Pileri A; Boccadoro M. | |
| Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue | 2018 | Ciavarella, S.; Vegliante, M.C.; Fabbri, M.; De Summa, S.; Melle, F.; Motta, G.; De Iuliis, V.; Opinto, G.; Enjuanes, A.; Rega, S.; Gulino, A.; Agostinelli, C.; Scattone, A.; Tommasi, S.; Mangia, A.; Mele, F.; Simone, G.; Zito, A.F.; Ingravallo, G.; Vitolo, U.; Chiappella, A.; Tarella, C.; Gianni, A.M.; Rambaldi, A.; Zinzani, P.L.; Casadei, B.; Derenzini, E.; Loseto, G.; Pileri, A.; Tabanelli, V.; Fiori, S.; Rivas-Delgado, A.; López-Guillermo, A.; Venesio, T.; Sapino, A.; Campo, E.; Tripodo, C.; Guarini, A.; Pileri, S.A. | |
| Dose- intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. | 1999 | Palumbo A; Triolo S; Argentino C; Bringhen S; Dominietto A; Rus C; Omedè P; Tarella C; Pileri A; Boccadoro M |